Osprey makes successful landing on ASX

Osprey Medical ($OSP) has reportedly caught the eye of investors with an auspicious beginning in its first day trading on the Australian Securities Exchange (ASX). It made its debut with a 5% premium listing at 42 cents, 2 cents above its issue price, The Australian notes. The news comes a month after the company announced that it had raised $20 million Australian ($20.8 million) in its IPO. "With the success of the IPO, we are now very strongly placed for our pivotal clinical trial in the U.S. and the commercialization of the CINCOR system, initially in Germany and the Netherlands," said Mike McCormick, Osprey president and CEO. The CINCOR system is designed to guard against contrast induced nephropathy, a type of kidney damage, in high-risk patients undergoing certain heart procedures. Osprey release | More

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.